Danaher (NYSE:DHR) Releases Earnings Results, Beats Expectations By $0.20 EPS

Danaher (NYSE:DHR) announced its quarterly earnings data on Tuesday. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20, Briefing.com reports. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.48%. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.36 earnings per share.

Danaher Price Performance

Danaher stock opened at $250.41 on Thursday. The firm has a 50-day moving average price of $249.00 and a 200-day moving average price of $230.78. The firm has a market capitalization of $185.44 billion, a PE ratio of 42.44, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Transactions at Danaher

In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DHR. Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and upped their target price for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday. TD Cowen upped their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Robert W. Baird upped their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $270.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.